Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Allergic vasculitis caused by Vigabatrin]

L Dieterle1, E W Becker, P A Berg

  • 1Erwachsenenklinik am Epilepsiezentrum Kork, Medizinischen Universitätsklinik Tübingen.

Der Nervenarzt
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Micro-algae as a source of protein.

Biotechnology advances·2007
Same author

[Neuroimmunologic aspects of functional-somatic syndromes].

Deutsche medizinische Wochenschrift (1946)·2005
Same author

[Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].

Deutsche medizinische Wochenschrift (1946)·2004
Same author

Methods for the in vitro determination of an individual disposition towards TH1- or TH2-reactivity by the application of appropriate stimulatory antigens.

Clinical and experimental immunology·2003
Same author

Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study.

International journal of clinical pharmacology and therapeutics·2003
Same author

Analysis of immunoregulatory T-helper cell subsets in patients with multiple sclerosis: relapsing-progressive course correlates with enhanced T H1, relapsing-remitting course with enhanced T H0 reactivity.

Journal of neuroimmunology·2002
Same journal

[When brain abscesses run in the family…].

Der Nervenarzt·2026
Same journal

[Digital health applications and adherence in depression: a qualitative study from the perspective of healthcare providers].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[Rare genetic diseases with frequent mental symptoms].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
See all related articles

Vigabatrin, an epilepsy drug, can cause allergic vasculitis and vision loss. Cortisone therapy successfully treated the patient's condition, highlighting the importance of monitoring for adverse effects.

Area of Science:

  • Neurology
  • Ophthalmology
  • Immunology

Background:

  • Focal epilepsy treatment often involves add-on therapies for drug-resistant cases.
  • Vigabatrin is an established antiepileptic medication used in specific treatment-resistant epilepsy scenarios.
  • Adverse effects of antiepileptic drugs require careful monitoring and prompt diagnosis.

Observation:

  • A patient with medically refractory focal epilepsy was treated with vigabatrin.
  • Six months into therapy, the patient developed symptoms suggestive of vasculitis.
  • Clinical presentation included unilateral anterior ischemic optic neuropathy, vision impairment, and visual field constriction.

Findings:

  • Diagnosis of vigabatrin-induced allergic vasculitis was confirmed via lymphocyte transformation test and clinical progression.

Related Experiment Videos

  • The patient's vision impairment and visual field loss were directly linked to the allergic vasculitis.
  • Histopathological examination of affected tissues would further confirm the vasculitic process.

    • Implications:

    • This case underscores the potential for vigabatrin to induce severe systemic adverse reactions like allergic vasculitis.
    • Early diagnosis and intervention, including cessation of the offending drug and appropriate treatment (e.g., corticosteroids), are crucial for managing vigabatrin-induced vasculitis.
    • Ophthalmologic monitoring is essential for patients on long-term vigabatrin therapy due to the risk of optic neuropathy.